Thursday 16 October, 2025
Introduction/objective: Diarylquinolines (DARQs) have become essential in treatment regimens against Mycobacterium tuberculosis. TBAJ-587 is a 2nd generation DARQ being developed…
Read morePoster: Drug/Disease Modelling - Infection
A novel mechanistic viral dynamics modeling (MVDM) framework to characterize the effect of combination therapies in chronic hepatitis B and evaluate the influence of individual characteristics in the Piranga phase 2 platform study
Thursday 16 October, 2025
Introduction: Existing mechanistic models of chronic hepatitis B infection (CHB) focus on a subset of biomarkers that do not capture…
Read moreExpansion of a mechanistic model of recurrent respiratory infections in children to the elderly and chronic obstructive pulmonary disease populations
Thursday 16 October, 2025
OBJECTIVES OM-85 is a bacterial lysate used to prevent recurrent respiratory tract infections (RTIs) in children [1]. To support OM-85…
Read morePopulation Pharmacokinetic Analysis of Tenofovir Alafenamide (TAF) and Tenofovir (TFV) in Adolescents and Children with HIV-1
Thursday 16 October, 2025
Objectives: Tenofovir alafenamide (TAF) is a second generation oral prodrug of tenofovir (TFV), a nucleotide analog that inhibits HIV type…
Read morePharmacogenetics-guided isoniazid dosing in individuals with tuberculosis and HIV
Thursday 16 October, 2025
Keywords: Pharmacogenetics, isoniazid, NAT2 polymorphism, tuberculosis, HIV, personalized medicine Background: Tuberculosis (TB) remains a major global health challenge, particularly in…
Read moreExtrapolation of Lung Pharmacokinetics from Preclinical Species and Implications for Dose Selection in Humans: the role of physiologically based pharmacokinetic modeling in the development of antitubercular drugs.
Thursday 16 October, 2025
Objectives Tuberculosis (TB) is a major global infectious disease, primarily affecting the lungs (pulmonary TB). Active disease leads to focal…
Read moreThe impact of bacterial growth kinetics on predicted antibiotic efficacy under different pharmacodynamic model assumptions: An in vivo case example
Thursday 16 October, 2025
Introduction: In recent years, the translational potential of longitudinal pharmacokinetic/ pharmacodynamic (PKPD) models, describing antibiotic effects on bacterial growth, has…
Read moreFree IL-6 Following Treatment with Ziltivekimab in a Population with Moderate-to-Severe Chronic Kidney Disease
Thursday 16 October, 2025
Objective: Ziltivekimab is a human monoclonal antibody that targets interleukin 6 (IL-6), a pro-inflammatory cytokine involved in various inflammatory processes….
Read moreTarget site pharmacokinetics-pharmacodynamics of DNDI-6148 in a murine Leishmania major skin infection model: integrating parasite bioluminescent imaging and lesion dynamics
Thursday 16 October, 2025
Introduction: Cutaneous leishmaniasis (CL), the most common form of leishmaniasis, is a neglected tropical disease caused by Leishmania (L.) parasites…
Read moreSimulation-based prediction of pharmacokinetic/pharmacodynamic (PK/PD) index for Linezolid to treat cerebral infections in critically ill patients
Thursday 16 October, 2025
Objectives Opimization of antibiotic dosing regimens is essentially based on empirical pharmacokinetic/pharmacodynamic (PK/PD) indices related to minimal inhibitory concentration (MIC)…
Read more